Identifying BPDCN: Navigating the Differential Diagnosis

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) remains one of the most challenging hematologic malignancies to diagnose due to its protean clinical presentation. In this episode, Andrew A. Lane, MD, PhD, Dana-Farber Cancer Institute, explains this distinct disease, and its historic outcomes with more aggressive treatment regimens.

Historically categorized under various names, it was officially recognized by the World Health Organization in 2006 as a distinct entity. Clinically, BPDCN behaves similarly to acute myeloid leukemia (AML) but possesses a unique tropism for the skin. Approximately 80% to 90% of patients present with cutaneous lesions. In nearly half of these cases, the disease appears restricted to the skin at the time of initial biopsy.

Of note, BPDCN is inherently a disseminated, systemic disease. Regardless of whether a patient presents with a single skin lesion or widespread lymphadenopathy, the therapeutic approach remains aggressive. Diagnostic protocols must include a bone marrow biopsy and, crucially, a lumbar puncture. Central nervous system (CNS) involvement is common at the time of diagnosis, and failing to stage can lead to early relapse.

The typical patient profile trends older, with a median age in the late 60s to early 70s. This demographic presents a significant hurdle for traditional intensive chemotherapy, which is often poorly tolerated. Historically, outcomes were dismal with non-specific induction regimens. The current standard of care has shifted away from broad-spectrum cytotoxic agents toward precision medicine.

According to Lane, identifying the "triad" of CD123, CD4, and CD56 expression via flow cytometry is the gold standard for confirming BPDCN. Once confirmed, the primary clinical goal is the induction of a complete remission (CR) to facilitate an allogeneic stem cell transplant, which remains the only curative pathway. In this episode, Lane establishes the baseline necessity for rapid, accurate identification and systemic staging to improve the long-term prognosis for high-risk patients.